BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors

Kinase inhibitors are accepted treatment for metastatic melanomas that harbor specific driver mutations in BRAF or KIT, but only 40–50% of cases are positive. To uncover other potential targetable mutations, we performed whole-genome sequencing of a highly aggressive BRAF (V600) and KIT (W557, V559,...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Dahlman, Kimberly Brown, Xia, Junfeng, Hutchinson, Katherine, Ng, Charles, Hucks, Donald, Jia, Peilin, Atefi, Mohammad, Su, Zengliu, Branch, Suzanne, Lyle, Pamela L., Hicks, Donna J., Bozon, Viviana, Glaspy, John A., Rosen, Neal, Solit, David B., Netterville, James L., Vnencak-Jones, Cindy L., Sosman, Jeffrey A., Ribas, Antoni, Zhao, Zhongming, Pao, William
Формат: Artigo
Язык:Inglês
Опубликовано: 2012
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3449158/
https://ncbi.nlm.nih.gov/pubmed/22798288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0097
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы